• Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue.
  • Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage.
  • With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair.

LOS ANGELES, CA - August 28, 2026 (NEWMEDIAWIRE) - Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it?

One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

View the original release on www.newmediawire.com